Sign Up
QUESTIONS| Event Date/Time: Jun 26, 2012 | End Date/Time: Jun 27, 2012 |
| Registration Date: Jun 24, 2012 | |
| Early Registration Date: May 15, 2012 |
Report as SpamDescription
Cell Based Assays 2012
26th -27th June 2012 London UK
Cell Based Assays Conference is a much awaited symposium where latest developments on cell based assays and their significance to the strategic future of Research and Development in pharmaceutical industry etc will be discussed and debated. Here in Cell Based Assays Conference keynote speakers like Eberhard Krausz, Marianthi Papakosta, Marie H. Delmotte, Dr. Peter Horvath, Professor Marc Bickle etc will come and provide latest updates on cell based assays. Plenary sessions, debates and discussions will be very much beneficial
Key Speakers
Eberhard Krausz, Director, Assay Development & Target Validation, Enabling Biology, Janssen Research & Development
Marianthi Papakosta Scientific Director at Grunenthal GmbH
Marie H. Delmotte Lab Head - Cellular and Molecular Biology at Novartis
Dr. Xavier Leroy Project Promoter & Leader Associate Director Drug Discovery Dept. Actelion Pharmaceuticals Ltd
Dr. Jeroen van Bergeijk GPRD Research Neuroscience Molecular Biology & Biochemistry Abbott GmbH & Co. KG
Thomas Koblizek Senior Scientist R&D Lonza
Dr. Peter Horvath, Head of image and data analysis, ETH Zurich, Light Microscopy Centre.
Professor Marc Bickle Head of Technology Development Studio at Max Planck Institute of Molecular Cell Biology and Genetics
Remko de Pril Team Leader Target Discovery and High-Content Screening Galapagos
Professor David R. Greaves Professor of Inflammation Biology Sir William Dunn School of Pathology University of Oxford
Robin Ketteler MRC LMCB University College London
Rachel Russell Director and Head of the Plate Based Pharmacology Department Pfizer
Cell Based Assays 2012
Day 1 26th June 2012
09:00 Registration and refreshments
09:30 Opening address from the Chair
09:40 Quantitative analysis of cell-based high-content drug and siRNA screens - How can machine intelligence help?
Image quality enhancement (vignetting)
Image analysis of end point- and time-resolved data (segmentation, feature extraction, tracking)
Multi-parametric analysis of single cell-based assays using machine learning (classification, regression, method optimization, weakly-supervised approaches)
Statistical analysis and quality control issues
Dr. Peter Horvath, Head of image and data analysis, ETH Zurich, Light Microscopy Centre
10:20 Systematic analysis of complex signal transduction pathways using protein fragment complementation assays
Protein:protein interactions
Classical GPCR signaling
Non-classical GPCR pathways and interconnectivity
Examples for complex networks
The PCA working principle
Some PCA examples
Somatostatin homodimers/heterodimer data
CXCR4 agonist/antagonist data
Thomas Koblizek Senior Scientist R&D Lonza
11:00 Morning refreshments
11:20 Use of cell based GPCR assays to identify novel CB2 agonists and chemokine receptor antagonists
David R. Greaves Professor of Inflammation Biology Sir William
Dunn School of Pathology University of Oxford
12:00 Sponsor Speaking section contact tareef.ahmed@atta-online.co.uk for more detail
12:40 Networking lunch
13:40 Targeting endogenous stem cells for therapy
Targeting endogenous stem cells for therapy and related approaches (e.g. IPSCs).
Recruitment of (neuronal) stem and precursor cells for regeneration & neuroprotection
Targeting cancer stem cells for oncology
Hedgehog signaling
Dr. Jeroen van Bergeijk GPRD Research Neuroscience Molecular Biology & Biochemistry Abbott GmbH & Co. KG
14:20 Carcinogenicity risk assessment of Biologics using in vitro cell-based assays
Marie H. Delmotte Lab Head - Cellular and Molecular Biology at Novartis
15:00 Afternoon Refreshments
15:20 Sponsor Speaking section contact tareef.ahmed@atta-online.co.uk for more detail
16:00 Pores for thought; analyses of TRPV1 chimeras using a bespoke heat activation assay, demonstrate that differences in the pore domain confer species specific pharmacological sensitivity
Marianthi Papakosta Scientific Director at Grunenthal GmbH
16:40 Closing remarks from the Chair
16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting
Cell Based Assays 2012
Day2 27th June 2012
09:00 Registration and refreshments
09:30 Opening address from the Chair
09:40 Primary cells and 3D models in high-throughput screening
Robin Ketteler MRC LMCB University College London
10:20 Polarity markers as functional readouts of hepatic toxicity in 3D
use of bacterial artificial chromosome to ensure physiological levels of tpj1-cherry polarity marker expression
3 dimensional cell culture to ensure polarity and functional bile canaliculi system
generation of transgenic animals for primary cell culture
high throughput imaging of live polarised hepatocytes
automated image analysis
Marc Bickle Head of Technology Development Studio at Max Planck Institute of Molecular Cell Biology and Genetics
11:00 Morning refreshments
11:20 Application of in vitro 3D models for drug discovery
More complex and therefore physiologically more relevant cell-based assays will ultimately be more predictive than current 2D-based assays.
Technologies and assay set-up for medium-throughput compound screening in 3D (co-) cultures
High-content analysis is a versatile technology platform to capture complex cell-based assays.
Applications in oncology, virology and safety pharmacology
Eberhard Krausz, Director, Assay Development & Target Validation, Enabling Biology, Janssen Research & Development
12:00 Sponsor Speaking section contact tareef.ahmed@atta-online.co.uk for more detail
12:40 Networking lunch
13:40 plate based screening
Gene expression assay
Label-free as well as assay development
native neuronal cell types
Presentation from Pfizer
14:20 Beta-Arrestin 2 in Drug Discovery
Deorphanisation
HTS
Biased signaling
Scavanger
In-vitro to in-vivo
Xavier Leroy, Ph.D. Project Promoter & Leader Associate Director Drug Discovery Dept. Actelion Pharmaceuticals Ltd
15:00 Afternoon Refreshments
15:20 Sponsor Speaking section contact tareef.ahmed@atta-online.co.uk for more detail
16:00 High-Content screen for inhibitors of cell migration in cancer metastasis using adenoviral knock-down
high-throughput wound healing assay to identify novel genes involved in metastatic cell migration.
Genes whose knock-down inhibit cell migration
effect on the open wound
Remko de Pril Galapagos Team Leader Target Discovery and High-Content Screening
16:40 Closing remarks from the Chair
16:50 End of Day 2
Registration Form for Cell Based Assays 2012
24th-25th April 2012, London UK.
Standard Prices £499
Price for Academic, NGO and Government £299GROUP DISCOUNTS AVAILABLE
The conference fee includes refreshments, lunch, conference papers and access to the Document Portal containing all of the presentations.
Promotional Literature Distribution: Distribute of your company’s promotional literature to all conference attendees for £499+VAT
DELEGATE DETAILS
Please complete fully and clearly in capital letters and e-mail it to :
tareef.ahmed@atta-online.co.uk
Please photocopy for additional delegates.
Title:
Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by ATTA’s Terms and Conditions of Booking.
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.
26th -27th June 2012 London UK
Cell Based Assays Conference is a much awaited symposium where latest developments on cell based assays and their significance to the strategic future of Research and Development in pharmaceutical industry etc will be discussed and debated. Here in Cell Based Assays Conference keynote speakers like Eberhard Krausz, Marianthi Papakosta, Marie H. Delmotte, Dr. Peter Horvath, Professor Marc Bickle etc will come and provide latest updates on cell based assays. Plenary sessions, debates and discussions will be very much beneficial
Key Speakers
Eberhard Krausz, Director, Assay Development & Target Validation, Enabling Biology, Janssen Research & Development
Marianthi Papakosta Scientific Director at Grunenthal GmbH
Marie H. Delmotte Lab Head - Cellular and Molecular Biology at Novartis
Dr. Xavier Leroy Project Promoter & Leader Associate Director Drug Discovery Dept. Actelion Pharmaceuticals Ltd
Dr. Jeroen van Bergeijk GPRD Research Neuroscience Molecular Biology & Biochemistry Abbott GmbH & Co. KG
Thomas Koblizek Senior Scientist R&D Lonza
Dr. Peter Horvath, Head of image and data analysis, ETH Zurich, Light Microscopy Centre.
Professor Marc Bickle Head of Technology Development Studio at Max Planck Institute of Molecular Cell Biology and Genetics
Remko de Pril Team Leader Target Discovery and High-Content Screening Galapagos
Professor David R. Greaves Professor of Inflammation Biology Sir William Dunn School of Pathology University of Oxford
Robin Ketteler MRC LMCB University College London
Rachel Russell Director and Head of the Plate Based Pharmacology Department Pfizer
Cell Based Assays 2012
Day 1 26th June 2012
09:00 Registration and refreshments
09:30 Opening address from the Chair
09:40 Quantitative analysis of cell-based high-content drug and siRNA screens - How can machine intelligence help?
Image quality enhancement (vignetting)
Image analysis of end point- and time-resolved data (segmentation, feature extraction, tracking)
Multi-parametric analysis of single cell-based assays using machine learning (classification, regression, method optimization, weakly-supervised approaches)
Statistical analysis and quality control issues
Dr. Peter Horvath, Head of image and data analysis, ETH Zurich, Light Microscopy Centre
10:20 Systematic analysis of complex signal transduction pathways using protein fragment complementation assays
Protein:protein interactions
Classical GPCR signaling
Non-classical GPCR pathways and interconnectivity
Examples for complex networks
The PCA working principle
Some PCA examples
Somatostatin homodimers/heterodimer data
CXCR4 agonist/antagonist data
Thomas Koblizek Senior Scientist R&D Lonza
11:00 Morning refreshments
11:20 Use of cell based GPCR assays to identify novel CB2 agonists and chemokine receptor antagonists
David R. Greaves Professor of Inflammation Biology Sir William
Dunn School of Pathology University of Oxford
12:00 Sponsor Speaking section contact tareef.ahmed@atta-online.co.uk for more detail
12:40 Networking lunch
13:40 Targeting endogenous stem cells for therapy
Targeting endogenous stem cells for therapy and related approaches (e.g. IPSCs).
Recruitment of (neuronal) stem and precursor cells for regeneration & neuroprotection
Targeting cancer stem cells for oncology
Hedgehog signaling
Dr. Jeroen van Bergeijk GPRD Research Neuroscience Molecular Biology & Biochemistry Abbott GmbH & Co. KG
14:20 Carcinogenicity risk assessment of Biologics using in vitro cell-based assays
Marie H. Delmotte Lab Head - Cellular and Molecular Biology at Novartis
15:00 Afternoon Refreshments
15:20 Sponsor Speaking section contact tareef.ahmed@atta-online.co.uk for more detail
16:00 Pores for thought; analyses of TRPV1 chimeras using a bespoke heat activation assay, demonstrate that differences in the pore domain confer species specific pharmacological sensitivity
Marianthi Papakosta Scientific Director at Grunenthal GmbH
16:40 Closing remarks from the Chair
16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting
Cell Based Assays 2012
Day2 27th June 2012
09:00 Registration and refreshments
09:30 Opening address from the Chair
09:40 Primary cells and 3D models in high-throughput screening
Robin Ketteler MRC LMCB University College London
10:20 Polarity markers as functional readouts of hepatic toxicity in 3D
use of bacterial artificial chromosome to ensure physiological levels of tpj1-cherry polarity marker expression
3 dimensional cell culture to ensure polarity and functional bile canaliculi system
generation of transgenic animals for primary cell culture
high throughput imaging of live polarised hepatocytes
automated image analysis
Marc Bickle Head of Technology Development Studio at Max Planck Institute of Molecular Cell Biology and Genetics
11:00 Morning refreshments
11:20 Application of in vitro 3D models for drug discovery
More complex and therefore physiologically more relevant cell-based assays will ultimately be more predictive than current 2D-based assays.
Technologies and assay set-up for medium-throughput compound screening in 3D (co-) cultures
High-content analysis is a versatile technology platform to capture complex cell-based assays.
Applications in oncology, virology and safety pharmacology
Eberhard Krausz, Director, Assay Development & Target Validation, Enabling Biology, Janssen Research & Development
12:00 Sponsor Speaking section contact tareef.ahmed@atta-online.co.uk for more detail
12:40 Networking lunch
13:40 plate based screening
Gene expression assay
Label-free as well as assay development
native neuronal cell types
Presentation from Pfizer
14:20 Beta-Arrestin 2 in Drug Discovery
Deorphanisation
HTS
Biased signaling
Scavanger
In-vitro to in-vivo
Xavier Leroy, Ph.D. Project Promoter & Leader Associate Director Drug Discovery Dept. Actelion Pharmaceuticals Ltd
15:00 Afternoon Refreshments
15:20 Sponsor Speaking section contact tareef.ahmed@atta-online.co.uk for more detail
16:00 High-Content screen for inhibitors of cell migration in cancer metastasis using adenoviral knock-down
high-throughput wound healing assay to identify novel genes involved in metastatic cell migration.
Genes whose knock-down inhibit cell migration
effect on the open wound
Remko de Pril Galapagos Team Leader Target Discovery and High-Content Screening
16:40 Closing remarks from the Chair
16:50 End of Day 2
Registration Form for Cell Based Assays 2012
24th-25th April 2012, London UK.
Standard Prices £499
Price for Academic, NGO and Government £299GROUP DISCOUNTS AVAILABLE
The conference fee includes refreshments, lunch, conference papers and access to the Document Portal containing all of the presentations.
Promotional Literature Distribution: Distribute of your company’s promotional literature to all conference attendees for £499+VAT
DELEGATE DETAILS
Please complete fully and clearly in capital letters and e-mail it to :
tareef.ahmed@atta-online.co.uk
Please photocopy for additional delegates.
Title:
Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by ATTA’s Terms and Conditions of Booking.
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.
Venue
Restrictions
Invitation Only
